At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AAPG ASCENTAGE PHARMA GROUP
Closed 09-04 16:00:00 EDT
17.62
+0.26
+1.47%
盘后17.62
+0.000.00%
19:52 EDT
High17.75Low17.60Vol5.08K
Open17.70D1 Closing17.36Amplitude0.84%
Mkt Cap1.64BTradable Cap1.26BTotal Shares93.33M
T/O89.16KT/O Rate0.01%Tradable Shares71.58M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on NA Companies: PACS Group Inc (PACS) and Ascentage Pharma Group International Unsponsored ADR (AAPG)
TIPRANKS  ·  09-02 21:10
Analysts Offer Insights on NA Companies: PACS Group Inc (PACS) and Ascentage Pharma Group International Unsponsored ADR (AAPG)
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
GlobeNewswire  ·  09-02 20:00
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
Oppenheimer Keeps Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)
TIPRANKS  ·  08-21
Oppenheimer Keeps Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)
Ascentage Pharma H1 Loss Widens, Revenue Rises
MT Newswires Live  ·  08-20
Ascentage Pharma H1 Loss Widens, Revenue Rises
Reported Earlier, Ascentage Pharma Group H1 EPS $(0.32) Beats $(0.44) Estimate, Sales $44.541M Beat $24.070M Estimate
Benzinga Earnings  ·  08-20
Reported Earlier, Ascentage Pharma Group H1 EPS $(0.32) Beats $(0.44) Estimate, Sales $44.541M Beat $24.070M Estimate
Ascentage Pharma Reports 2026 Interim Results: Strengthening Commercial Engine and Accelerating Global Expansion
Stock News  ·  08-20
Ascentage Pharma Reports 2026 Interim Results: Strengthening Commercial Engine and Accelerating Global Expansion
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
GlobeNewswire  ·  08-20
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
GlobeNewswire  ·  08-13
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Earning Preview: ASCENTAGE PHARMA GROUP this quarter’s revenue is expected to increase by 58.18%, and institutional views are bullish
Earnings Agent  ·  08-12
Earning Preview: ASCENTAGE PHARMA GROUP this quarter’s revenue is expected to increase by 58.18%, and institutional views are bullish
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
GlobeNewswire  ·  08-05
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Ascentage Pharma appoints Miyara as CBO, Ziegler as CCO
TIPRANKS  ·  08-03
Ascentage Pharma appoints Miyara as CBO, Ziegler as CCO
ASCENTAGE PHARMA GROUP Appoints Two Key Executives to Lead Global Business and Commercial Operations
Stock News  ·  08-03
ASCENTAGE PHARMA GROUP Appoints Two Key Executives to Lead Global Business and Commercial Operations
Press Release: Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Dow Jones  ·  08-03
Press Release: Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
GlobeNewswire  ·  07-27
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
Ascentage Pharma files to sell American Depositary Shares, no amount given
TIPRANKS  ·  07-20
Ascentage Pharma files to sell American Depositary Shares, no amount given
ASCENTAGE PHARMA Announces Grant of 440,700 Restricted Share Units Under 2021 Plan
Stock News  ·  06-30
ASCENTAGE PHARMA Announces Grant of 440,700 Restricted Share Units Under 2021 Plan
Ascentage Pharma announces clinical updates from EHA2026
TIPRANKS  ·  06-15
Ascentage Pharma announces clinical updates from EHA2026
ASCENTAGE PHARMA GROUP (ASX: 06855) Discloses Multiple Clinical Advances at 2026 European Hematology Association Congress
Stock News  ·  06-15
ASCENTAGE PHARMA GROUP (ASX: 06855) Discloses Multiple Clinical Advances at 2026 European Hematology Association Congress
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
GlobeNewswire  ·  06-15
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
ASCENTAGE PHARMA Group Acquires 110,000 Shares for 2022 Restricted Stock Unit Plan
Stock News  ·  06-11
ASCENTAGE PHARMA Group Acquires 110,000 Shares for 2022 Restricted Stock Unit Plan

Introduction

Company Name.
ASCENTAGE PHARMA GROUP
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ascentage Pharma Group is a holding company primarily engaged in the discovery, development, and commercialization of therapeutics for hematologic malignancies. Its core business focuses on developing and selling novel small-molecule therapies targeting cancer, hepatitis B, and age-related diseases. Key products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), and APG-5918, which are mainly used to treat hematologic malignancies such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and multiple myeloma. The company primarily operates in the domestic Chinese market.
Issue price:
--